Fig. 1

Expression of MKRN2 in NSCLC is associated with poor clinical prognosis. a MKRN2 protein level analyzed by immunohistochemistry in (i) alveolar and (ii) normal bronchial epithelial cells, (iii) well-differentiated squamous cell carcinoma and (iv) adenocarcinoma, and (v) poorly differentiated squamous cell carcinoma and (vi) adenocarcinoma. b Survival of NSCLC patients with high and low MKRN2 expression analyzed based on Kaplan–Meier curves. Hazard ratio (HR) and P value are indicated. c Immunofluorescence assays were performed to detect MKRN2 localization in human normal bronchial epithelial and NSCLC cell lines. MKRN2 was located in the cytoplasm and nucleus. d MKRN2 levels in HBE cells and six NSCLC cell lines according to western blot analysis. Relative quantification analysis was based on grayscale values